Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39666006.
- Also identified by DOI 10.1021/acsnano.4c11259.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chemoresistance remains a long-standing challenge after cancer treatment. Over the last two decades, RNA interference (RNAi) has emerged as a gene therapy modality to sensitize cancer cells to chemotherapy. However, the use of RNAi, specifically small-interfering RNA (siRNA), is hindered by biological barriers that limit its intracellular delivery. Nanoparticles can overcome these barriers by protecting siRNA in physiological environments and facilitating its delivery to cancer cells. In this review, we discuss the development of nanomaterials for siRNA delivery in cancer therapy, current challenges, and future perspectives for their implementation to overcome cancer chemoresistance.
Medical subject headings
- RNA, Small Interfering
- Neoplasms
- Drug Resistance, Neoplasm
- Nanostructures